Clinical trial
A Phase 1-2 Study of ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
NCT03897543 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1-2 Study of ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
- Lead sponsor
- Abivax S.A.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 18, 2020
- Completion date
- April 14, 2022
- Enrollment
- 10 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.